Tags : QurAlis

QurAlis Signs a License Agreement with Eli Lilly for its

Shots: QurAlis in-licenses Eli Lilly’s excitotoxicity targeted pre-clinical compounds with disease-modifying potential in ALS The collaboration allows QurAlis to foster its ALS Pipeline with the addition of Lilly’s pre-clinical candidates QurAlis’ excitotoxicity research program aims to prevent neuronal excitability with specifically targeted small molecule drugs and prevent disease progression in ALS patients Click here to read […]Read More